Literature DB >> 27402390

[Not Available].

Stephanie E Combs1,2, Friederike Schmidt-Graf3, Bernhard Meyer4.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27402390     DOI： 10.1007/s00066-016-1016-6

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  7 in total

1.  Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.

Authors:  Jan C Buckner; Edward G Shaw; Stephanie L Pugh; Arnab Chakravarti; Mark R Gilbert; Geoffrey R Barger; Stephen Coons; Peter Ricci; Dennis Bullard; Paul D Brown; Keith Stelzer; David Brachman; John H Suh; Christopher J Schultz; Jean-Paul Bahary; Barbara J Fisher; Harold Kim; Albert D Murtha; Erica H Bell; Minhee Won; Minesh P Mehta; Walter J Curran
Journal:  N Engl J Med       Date:  2016-04-07       Impact factor: 91.245

2.  Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.

Authors:  Benedikt Wiestler; David Capper; Volker Hovestadt; Martin Sill; David T W Jones; Christian Hartmann; Joerg Felsberg; Michael Platten; Wolfgang Feiden; Kathy Keyvani; Stefan M Pfister; Otmar D Wiestler; Richard Meyermann; Guido Reifenberger; Thorsten Pietsch; Andreas von Deimling; Michael Weller; Wolfgang Wick
Journal:  Neuro Oncol       Date:  2014-07-15       Impact factor: 12.300

3.  Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02.

Authors:  Roshan S Prabhu; Minhee Won; Edward G Shaw; Chen Hu; David G Brachman; Jan C Buckner; Keith J Stelzer; Geoffrey R Barger; Paul D Brown; Mark R Gilbert; Minesh P Mehta
Journal:  J Clin Oncol       Date:  2014-01-13       Impact factor: 44.544

4.  Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial.

Authors:  M J van den Bent; D Afra; O de Witte; M Ben Hassel; S Schraub; K Hoang-Xuan; P-O Malmström; L Collette; M Piérart; R Mirimanoff; A B M F Karim
Journal:  Lancet       Date:  2005 Sep 17-23       Impact factor: 79.321

5.  NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.

Authors:  Wolfgang Wick; Christian Hartmann; Corinna Engel; Mandy Stoffels; Jörg Felsberg; Florian Stockhammer; Michael C Sabel; Susanne Koeppen; Ralf Ketter; Richard Meyermann; Marion Rapp; Christof Meisner; Rolf D Kortmann; Torsten Pietsch; Otmar D Wiestler; Ulrike Ernemann; Michael Bamberg; Guido Reifenberger; Andreas von Deimling; Michael Weller
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

6.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

7.  Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

Authors:  Martin J van den Bent; Alba A Brandes; Martin J B Taphoorn; Johan M Kros; Mathilde C M Kouwenhoven; Jean-Yves Delattre; Hans J J A Bernsen; Marc Frenay; Cees C Tijssen; Wolfgang Grisold; László Sipos; Roelien H Enting; Pim J French; Winand N M Dinjens; Charles J Vecht; Anouk Allgeier; Denis Lacombe; Thierry Gorlia; Khê Hoang-Xuan
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544
  7 in total
  1 in total

1.  Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas.

Authors:  Juliana Watson; Alexander Romagna; Hendrik Ballhausen; Maximilian Niyazi; Stefanie Lietke; Sebastian Siller; Claus Belka; Niklas Thon; Silke Birgit Nachbichler
Journal:  Radiat Oncol       Date:  2020-12-09       Impact factor: 3.481
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.